These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 22555466)
1. Models for the study of Clostridium difficile infection. Best EL; Freeman J; Wilcox MH Gut Microbes; 2012; 3(2):145-67. PubMed ID: 22555466 [TBL] [Abstract][Full Text] [Related]
2. PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function σ factors in Clostridium difficile. Ho TD; Ellermeier CD Infect Immun; 2011 Aug; 79(8):3229-38. PubMed ID: 21628514 [TBL] [Abstract][Full Text] [Related]
3. Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models. Vitucci JC; Pulse M; Tabor-Simecka L; Simecka J BMC Microbiol; 2020 Feb; 20(1):27. PubMed ID: 32024477 [TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Vedantam G; Clark A; Chu M; McQuade R; Mallozzi M; Viswanathan VK Gut Microbes; 2012; 3(2):121-34. PubMed ID: 22555464 [TBL] [Abstract][Full Text] [Related]
5. The role of toxin A and toxin B in Clostridium difficile infection. Kuehne SA; Cartman ST; Heap JT; Kelly ML; Cockayne A; Minton NP Nature; 2010 Oct; 467(7316):711-3. PubMed ID: 20844489 [TBL] [Abstract][Full Text] [Related]
6. The HtrA-like protease CD3284 modulates virulence of Clostridium difficile. Bakker D; Buckley AM; de Jong A; van Winden VJ; Verhoeks JP; Kuipers OP; Douce GR; Kuijper EJ; Smits WK; Corver J Infect Immun; 2014 Oct; 82(10):4222-32. PubMed ID: 25047848 [TBL] [Abstract][Full Text] [Related]
7. The state of play of rodent models for the study of Brosse A; Coullon H; Janoir C; Péchiné S J Med Microbiol; 2024 Jul; 73(7):. PubMed ID: 39028257 [No Abstract] [Full Text] [Related]
8. Murine models to study Clostridium difficile infection and transmission. Lawley TD; Young VB Anaerobe; 2013 Dec; 24():94-7. PubMed ID: 24076318 [TBL] [Abstract][Full Text] [Related]
15. Need for clinicopathologic correlation of Clostridium difficile colitis in view of molecular diagnosis. Guarner J; Kraft CS Clin Infect Dis; 2012 Jan; 54(1):156. PubMed ID: 22187416 [No Abstract] [Full Text] [Related]
16. Two-year analysis of Clostridium difficile ribotypes associated with increased severity. Herbert R; Hatcher J; Jauneikaite E; Gharbi M; d'Arc S; Obaray N; Rickards T; Rebec M; Blandy O; Hope R; Thomas A; Bamford K; Jepson A; Sriskandan S J Hosp Infect; 2019 Dec; 103(4):388-394. PubMed ID: 31220480 [TBL] [Abstract][Full Text] [Related]
17. The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses. Bassotti G; Marchegiani A; Marconi P; Fettucciari K Microbiologyopen; 2020 Aug; 9(8):e1061. PubMed ID: 32657021 [TBL] [Abstract][Full Text] [Related]
18. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. Sirard S; Valiquette L; Fortier LC J Clin Microbiol; 2011 Dec; 49(12):4040-6. PubMed ID: 21956985 [TBL] [Abstract][Full Text] [Related]
19. In vivo commensal control of Clostridioides difficile virulence. Girinathan BP; DiBenedetto N; Worley JN; Peltier J; Arrieta-Ortiz ML; Immanuel SRC; Lavin R; Delaney ML; Cummins CK; Hoffman M; Luo Y; Gonzalez-Escalona N; Allard M; Onderdonk AB; Gerber GK; Sonenshein AL; Baliga NS; Dupuy B; Bry L Cell Host Microbe; 2021 Nov; 29(11):1693-1708.e7. PubMed ID: 34637781 [TBL] [Abstract][Full Text] [Related]
20. Measuring the impact of Clostridium difficile Infection with the NAP1 strain on severity and mortality. Rao K Clin Infect Dis; 2014 Oct; 59(8):1193-4. PubMed ID: 24982035 [No Abstract] [Full Text] [Related] [Next] [New Search]